Your session is about to expire
← Back to Search
Cancer Diagnostic Device
EsoGuard for Barrett's Esophagus (ESOGUARDBE1 Trial)
N/A
Waitlist Available
Research Sponsored by Lucid Diagnostics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Awards & highlights
Summary
This trial uses the EsoGuard test and EsoCheck device to screen high-risk individuals for Barrett's Esophagus and esophageal cancer by collecting and testing cells from the esophagus.
Eligible Conditions
- Barrett's Esophagus
- Esophageal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Primary Efficacy
Secondary outcome measures
Secondary Efficacy
Other outcome measures
Safety of EsoCheck device administration
Trial Design
1Treatment groups
Experimental Treatment
Group I: EsoCheck vs. EGD with or without biopsiesExperimental Treatment1 Intervention
All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EsoGuard
2020
N/A
~150
Find a Location
Who is running the clinical trial?
Lucid Diagnostics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,582 Total Patients Enrolled
Randy Brown, MSStudy DirectorLucid Diagnostics
Michelle McDermottStudy DirectorLucid Diagnostics
1 Previous Clinical Trials
470 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger